SARS-CoV-2 infection and COVID‒19 in Gaucher disease : indications for vaccination
At the start of the pandemic caused by the novel coronavirus (SARS-CoV-2), the Gaucher disease community anticipated that infection with this emerging viral pathogen would be associated with high morbidity and mortality in individuals with this chronic metabolic disorder. Surprisingly, however, preliminary studies suggest that Gaucher disease does not confer a higher risk of severe, life-threatening effects of SARS-CoV-2 infection, and no severe cases have been reported in large cohorts of patients from the United States, Europe and Israel. It is thought that the accumulation of glucocerebroside in the cells of Gaucher patients may promote immune tolerance rather than inflammation on exposure to SARS-CoV-2. We review here the current concepts of Gaucher disease and SARS-CoV-2 infection, focusing particularly on general prevention and vaccination. We also discuss the susceptibility to COVID-19 of patients with inborn errors of type 1 interferon (IFNα and IFNω) immunity. Orv Hetil. 2021; 162(24): 938-942.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:162 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 162(2021), 24 vom: 13. Juni, Seite 938-942 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
SARS-CoV-2-fertőzés és COVID-19 Gaucher-kóros betegekben: a védőoltás javallata |
|---|
| Beteiligte Personen: |
Maródi, László [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.06.2021 Date Revised 22.06.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2021.32272 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326680004 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326680004 | ||
| 003 | DE-627 | ||
| 005 | 20231225195122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2021.32272 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1088.xml |
| 035 | |a (DE-627)NLM326680004 | ||
| 035 | |a (NLM)34120104 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Maródi, László |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 infection and COVID‒19 in Gaucher disease |b indications for vaccination |
| 246 | 3 | 3 | |a SARS-CoV-2-fertőzés és COVID-19 Gaucher-kóros betegekben: a védőoltás javallata |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.06.2021 | ||
| 500 | |a Date Revised 22.06.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a At the start of the pandemic caused by the novel coronavirus (SARS-CoV-2), the Gaucher disease community anticipated that infection with this emerging viral pathogen would be associated with high morbidity and mortality in individuals with this chronic metabolic disorder. Surprisingly, however, preliminary studies suggest that Gaucher disease does not confer a higher risk of severe, life-threatening effects of SARS-CoV-2 infection, and no severe cases have been reported in large cohorts of patients from the United States, Europe and Israel. It is thought that the accumulation of glucocerebroside in the cells of Gaucher patients may promote immune tolerance rather than inflammation on exposure to SARS-CoV-2. We review here the current concepts of Gaucher disease and SARS-CoV-2 infection, focusing particularly on general prevention and vaccination. We also discuss the susceptibility to COVID-19 of patients with inborn errors of type 1 interferon (IFNα and IFNω) immunity. Orv Hetil. 2021; 162(24): 938-942 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACE | |
| 650 | 4 | |a APECED | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID–19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 162(2021), 24 vom: 13. Juni, Seite 938-942 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:162 |g year:2021 |g number:24 |g day:13 |g month:06 |g pages:938-942 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2021.32272 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 162 |j 2021 |e 24 |b 13 |c 06 |h 938-942 | ||